看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | Yes | No |
| Is net profit margin increasing? | Yes | Yes |
| Is asset turnover increasing? | Yes | No |
| Is equity multiplier increasing? | Yes | Yes |
| Competitors Used |
|---|
| CANbridge Pharmaceuticals Inc. |
| Keymed Biosciences Inc. |
| Jiangsu Aidea Pharmaceutical Co., Ltd. |
| Abbisko Cayman Limited |
| InnoCare Pharma Limited |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| 1,228 | 2,162 | 688,488 | 2,256 | 9,969 | CSPH.F | |||
| Return On Equity | ||||||||
| Latest Twelve Months | 172% | -19% | -12% | 1% | -6% | -22% | ||
| Fiscal Year - 1 | -282% | -11% | -7% | -20% | -9% | -81% | ||
| Fiscal Year - 2 | -97% | -9% | -10% | NA | -13% | -109% | ||
| Fiscal Year - 3 | 205% | -304% | -2% | -253% | -1% | -92% | ||
| Fiscal Year - 4 | 62% | NA | 4% | NA | -788% | -45% | ||
| Fiscal Year - 5 | 22% | NA | 6% | 29% | 110% | NA | ||
| Average | 14% | -86% | -3% | -61% | -118% | -70% | ||
| Median | 42% | -15% | -4% | -9% | -7% | -81% | ||
| Benchmarks | Ticker | |||||||
| CANbridge Pharmaceuticals Inc. | SEHK:1228 | |||||||
| Keymed Biosciences Inc. | SEHK:2162 | |||||||
| Jiangsu Aidea Pharmaceutical Co., Ltd. | SHSE:688488 | |||||||
| Abbisko Cayman Limited | SEHK:2256 | |||||||
| InnoCare Pharma Limited | SEHK:9969 | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | May-03 | Dec-05 | Jan-85 | Mar-06 | Apr-27 | CSPH.F | ||
| Latest Fiscal Year | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| LTM Period | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| Revenues | ||||||||
| Latest Twelve Months | 85 | 428 | 419 | 504 | 1,009 | 407 | ||
| Fiscal Year | 85 | 428 | 419 | 504 | 1,009 | 407 | ||
| Fiscal Year - 1 | 103 | 354 | 411 | 19 | 739 | 464 | ||
| Fiscal Year - 2 | 79 | 100 | 244 | NA | 625 | 481 | ||
| Fiscal Year - 3 | 31 | 110 | 256 | 23 | 1,043 | 244 | ||
| Fiscal Year - 4 | 12 | NA | 289 | NA | 1 | 1,039 | ||
| Fiscal Year - 5 | 1 | NA | 345 | 4 | 1 | NA | ||
| Net Income | ||||||||
| Latest Twelve Months | (443) | (515) | (130) | 28 | (441) | (91) | ||
| Fiscal Year | (443) | (515) | (130) | 28 | (441) | (91) | ||
| Fiscal Year - 1 | (379) | (359) | (76) | (432) | (631) | (367) | ||
| Fiscal Year - 2 | (483) | (308) | (124) | (496) | (887) | (903) | ||
| Fiscal Year - 3 | (1,077) | (3,887) | (30) | (1,810) | (65) | (1,920) | ||
| Fiscal Year - 4 | (846) | (819) | 40 | (707) | (391) | (1,221) | ||
| Fiscal Year - 5 | (218) | (168) | 34 | (134) | (2,141) | (2,069) | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 395 | 3,883 | 1,747 | 2,115 | 9,920 | 1,662 | ||
| Latest Fiscal Quarter | 117 | 3,767 | NA | 2,107 | 9,407 | 1,393 | ||
| Fiscal Year | 117 | 3,767 | NA | 2,107 | 9,407 | 1,393 | ||
| Fiscal Year - 1 | 395 | 3,883 | 1,747 | 2,115 | 9,920 | 1,662 | ||
| Fiscal Year - 2 | 702 | 3,932 | 1,656 | 2,490 | 10,329 | 1,638 | ||
| Fiscal Year - 3 | 893 | 3,934 | 1,435 | 2,655 | 7,398 | 2,271 | ||
| Fiscal Year - 4 | 586 | 530 | 1,447 | 666 | 4,538 | 3,763 | ||
| Fiscal Year - 5 | 89 | 659 | 781 | 320 | 2,616 | 2,951 | ||
| Fiscal Year - 6 | NA | NA | 709 | NA | 2,201 | 1,632 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | (40) | 2,986 | 1,126 | 1,981 | 7,148 | 457 | ||
| Latest Fiscal Quarter | (474) | 2,475 | 1,069 | 1,958 | 6,725 | 364 | ||
| Fiscal Year | (474) | 2,475 | 1,069 | 1,958 | 6,725 | 364 | ||
| Fiscal Year - 1 | (40) | 2,986 | 1,126 | 1,981 | 7,148 | 457 | ||
| Fiscal Year - 2 | 309 | 3,340 | 1,199 | 2,346 | 7,597 | 449 | ||
| Fiscal Year - 3 | 693 | 3,651 | 1,310 | 2,536 | 5,605 | 1,207 | ||
| Fiscal Year - 4 | (1,746) | (1,095) | 1,360 | (1,105) | 3,104 | 2,954 | ||
| Fiscal Year - 5 | (991) | (276) | 556 | (459) | (3,005) | 2,482 | ||
| Fiscal Year - 6 | NA | NA | 523 | NA | (904) | 515 | ||